Screener
Climb Bio, Inc. CLYM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $8,356 | $35,685 |
| Short-term marketable securities | 101,208 | 65,395 |
| Prepaid expenses and other current assets | 3,840 | 4,769 |
| Total current assets | 113,404 | 105,849 |
| Long-term marketable securities | 36,741 | 59,572 |
| Operating lease right-of-use assets | 447 | 505 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s cash & equivalents?
- Climb Bio, Inc. (CLYM) reported cash & equivalents of $8.36M in Q1 2026.
- How has Climb Bio, Inc.'s cash & equivalents changed year-over-year?
- Climb Bio, Inc.'s cash & equivalents decreased by 71.2% year-over-year, from $29.02M to $8.36M.
- What is the long-term trend for Climb Bio, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s cash & equivalents has grown at a 11.7% compound annual growth rate (CAGR), from $20.49M to $35.69M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Climb Bio, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude